NanHua Bio-medicine 南华生物

5 significant filings since 31 May 2026: 2 on regulatory inquiry, 1 on earnings pre-announcement and 1 on delisting warning lifted, and 1 other kind. The latest, on 10 Jul 2026: 2026-037 南华生物2026年半年度业绩预告的公告. On 10 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 220.54% to 277.94% from the same period a year earlier.
自 31 May 2026 起有 5 份重大公告：regulatory inquiry 2 份、earnings pre-announcement 1 份、delisting warning lifted 1 份，另有 1 类。最新一份（10 Jul 2026）：2026-037 南华生物2026年半年度业绩预告的公告。10 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 220.54% 至 277.94%。